The burgeoning trend in diabetes care is undoubtedly centered around GLP-1 receptor agonists , and BrightMeds is leading this wave . These powerful drugs, initially designed for treating type 2 diabetes, are now widely prescribed – or considered – for their significant ability to promote reduced